January 14, 2021

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

Beijing, CN, Henan, CN and Zurich-Schlieren, Switzerland, January 14, 2021. The Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics.

The leading cancer center in central China will partner with Proteomedix on a prospective study to assess the effectiveness of biomarker-based triage of patients with elevated levels or prostate specific antigen that are suspicious for clinically significant prostate cancer.

Professor Youlin Qiao, Chinese Academy of Medical Sciences Peking Union Medical College and Zhengzhou University Henan Cancer Hospital said: ”Prostate cancer is a common form of malignant tumor that severely threatens the health of men. There are 115,426* new cases of prostate cancer in China each year, and over 51,094 deaths due to the disease. It is the most common cancer amongst men from the ages of 55 onwards, it is also the third deadliest cancer in this age group. For this reason, prostate cancer diagnosis and effective patient management has the potential to significantly reduce the incidence of aggressive prostate cancer and reducing the burden of the disease.”

Professor Qiao said further: ”The goal of the partnership includes the assessment of novel biomarkers and their clinical application to prostate cancer prevention with the goal to improve current patient management in prostate cancer screening and prevention. In the longer term it is hoped that this effort will also help advance our understanding of mechanisms of the disease and potentially drug action.”

”Partnering with this renowned institution in China brings a wealth of clinical expertise to us that will advance the translation of biomarker-development and support the adoption of our novel Proclarix test and risks core into clinical practice” said Ralph Schiess, Chief Scientific Officer, Proteomedix.

About Zhengzhou University and Henan Cancer Hospital (ZUHCH)®

Henan Province is located in central China with a total population of 109 million. As a top Comprehensive Cancer Center integrated with clinical, research, prevention, teaching, Henan Cancer hospital was formally opened in 1984. With more than 3,000 beds, current staff are more than 3,360. The annual outpatient volume of the hospital is nearly 500,000 person-times, more than 140,000 patients are admitted, and more than 25,000 operations are performed. Meanwhile nearly 30 affiliated units are located here which include the Cancer Research Institute of Henan Province, Cancer Prevention and Treatment Office of Henan Province, Anti-Cancer Association of Henan Province, Cancer Diagnosis and Treatment Quality Control Center of Henan Province, Cancer Radiotherapy Centre of Henan Province and the Esophageal Cancer Treatment Center of Henan Province. The hospital has a full range of specialties, outstanding features and strong technical force with more than 50 clinical and medical technical departments, including the department of oncology, urology, and cancer prevention and control.

About Proclarix®

Proclarix®  is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer. Proclarix is currently not available in China.

About Proteomedix

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:

Dr. Ralph Schiess, CSO



*IRAC/WHO Globocan 2020